

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 56025

**Title:** The “six-and-twelve score” for outcome prediction of unresectable HCC treated with TACE. In-depth analysis from a multicenter French cohort

**Reviewer’s code:** 03261461

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Associate Professor

**Reviewer’s Country/Territory:** Egypt

**Author’s Country/Territory:** France

**Manuscript submission date:** 2020-04-13

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-04-13 19:16

**Reviewer performed review:** 2020-04-17 09:53

**Review time:** 3 Days and 14 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**[www.wjgnet.com](http://www.wjgnet.com)

#### **SPECIFIC COMMENTS TO AUTHORS**

it is very interesting manuscript , but i have few questions to the authors: 1- p 17 BCLC classification "BCLC stage A was defined as patients having tumor > 2 cm...." i think it is a mistake the correct is lesion < 2cm ,so please correct 2- You have 145 (45%) of the patients BCLC stage A why this patients do TACE ?? no other curative lines line RFA can be offered?? this need clarification as BCLC A can do curative therapy according to guidelines 3- Why you separate Marceillie cohort from the whole cohort i think this added too much tables and nearly the same findings